Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A single-centre, randomised, double-blind, placebo controlled, two 12 week period, cross-over phase III study to investigate the effect of rosiglitazone 4mg bd on the vasodilator response to hyperinsulinaemia in obese insulin resistant subjects.
rosiglitazone
BRL-049653/375
NCT00197132
Diabetes Mellitus, Type 2
Phase 3
 
An analysis-ready dataset is not available for this study.
February 2015

Powered by ideaPoint, Inc.